These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37406177)

  • 1. Management and outcome of COVID-19 in CTLA-4 insufficiency.
    Ochoa S; Abers MS; Rosen LB; Rump A; Howe K; Lieberman JA; Wright BL; Suez D; Krausz M; Grimbacher B; Lionakis MS; Uzel G
    Blood Adv; 2023 Oct; 7(19):5743-5751. PubMed ID: 37406177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications.
    Bodansky A; Vazquez SE; Chou J; Novak T; Al-Musa A; Young C; Newhams M; Kucukak S; Zambrano LD; Mitchell A; Wang CY; Moffitt K; Halasa NB; Loftis LL; Schwartz SP; Walker TC; Mack EH; Fitzgerald JC; Gertz SJ; Rowan CM; Irby K; Sanders RC; Kong M; Schuster JE; Staat MA; Zinter MS; Cvijanovich NZ; Tarquinio KM; Coates BM; Flori HR; Dahmer MK; Crandall H; Cullimore ML; Levy ER; Chatani B; Nofziger R; ; Geha RS; DeRisi J; Campbell AP; Anderson M; Randolph AG
    J Allergy Clin Immunol; 2023 Apr; 151(4):926-930.e2. PubMed ID: 36509151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
    Mathian A; Breillat P; Dorgham K; Bastard P; Charre C; Lhote R; Quentric P; Moyon Q; Mariaggi AA; Mouries-Martin S; Mellot C; Anna F; Haroche J; Cohen-Aubart F; Sterlin D; Zahr N; Gervais A; Le Voyer T; Bizien L; Amiot Q; Pha M; Hié M; Chasset F; Yssel H; Miyara M; Charneau P; Ghillani-Dalbin P; Casanova JL; Rozenberg F; Amoura Z; Gorochov G
    Ann Rheum Dis; 2022 Dec; 81(12):1695-1703. PubMed ID: 35973806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.
    Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H
    J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
    de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
    J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
    Bastard P; Rosen LB; Zhang Q; Michailidis E; Hoffmann HH; Zhang Y; Dorgham K; Philippot Q; Rosain J; Béziat V; Manry J; Shaw E; Haljasmägi L; Peterson P; Lorenzo L; Bizien L; Trouillet-Assant S; Dobbs K; de Jesus AA; Belot A; Kallaste A; Catherinot E; Tandjaoui-Lambiotte Y; Le Pen J; Kerner G; Bigio B; Seeleuthner Y; Yang R; Bolze A; Spaan AN; Delmonte OM; Abers MS; Aiuti A; Casari G; Lampasona V; Piemonti L; Ciceri F; Bilguvar K; Lifton RP; Vasse M; Smadja DM; Migaud M; Hadjadj J; Terrier B; Duffy D; Quintana-Murci L; van de Beek D; Roussel L; Vinh DC; Tangye SG; Haerynck F; Dalmau D; Martinez-Picado J; Brodin P; Nussenzweig MC; Boisson-Dupuis S; Rodríguez-Gallego C; Vogt G; Mogensen TH; Oler AJ; Gu J; Burbelo PD; Cohen JI; Biondi A; Bettini LR; D'Angio M; Bonfanti P; Rossignol P; Mayaux J; Rieux-Laucat F; Husebye ES; Fusco F; Ursini MV; Imberti L; Sottini A; Paghera S; Quiros-Roldan E; Rossi C; Castagnoli R; Montagna D; Licari A; Marseglia GL; Duval X; Ghosn J; ; ; ; ; ; ; ; ; ; ; Tsang JS; Goldbach-Mansky R; Kisand K; Lionakis MS; Puel A; Zhang SY; Holland SM; Gorochov G; Jouanguy E; Rice CM; Cobat A; Notarangelo LD; Abel L; Su HC; Casanova JL
    Science; 2020 Oct; 370(6515):. PubMed ID: 32972996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
    Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
    J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization.
    Lamacchia G; Mazzoni A; Spinicci M; Vanni A; Salvati L; Peruzzi B; Bencini S; Capone M; Carnasciali A; Farahvachi P; Rocca A; Kiros ST; Graziani L; Zammarchi L; Mencarini J; Colao MG; Caporale R; Liotta F; Cosmi L; Rossolini GM; Bartoloni A; Maggi L; Annunziato F
    J Clin Immunol; 2022 Oct; 42(7):1379-1391. PubMed ID: 35809212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Viurcos-Sanabria R; Manjarrez-Reyna AN; Solleiro-Villavicencio H; Rizo-Téllez SA; Méndez-García LA; Viurcos-Sanabria V; González-Sanabria J; Arroyo-Valerio A; Carrillo-Ruíz JD; González-Chávez A; León-Pedroza JI; Flores-Mejía R; Rodríguez-Cortés O; Escobedo G
    Front Immunol; 2022; 13():897995. PubMed ID: 35860236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19.
    Abolhassani H; Delavari S; Landegren N; Shokri S; Bastard P; Du L; Zuo F; Hajebi R; Abolnezhadian F; Iranparast S; Modaresi M; Vosughimotlagh A; Salami F; Aranda-Guillén M; Cobat A; Marcotte H; Zhang SY; Zhang Q; Rezaei N; Casanova JL; Kämpe O; Hammarström L; Pan-Hammarström Q
    J Allergy Clin Immunol; 2022 Nov; 150(5):1059-1073. PubMed ID: 36113674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.